The role of topotecan in the treatment of small cell lung cancer

Oncologist

Volumn 3, Issue 1, 1998, Pages 11-14

  Brahmer, Julie R ^a   Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Extensive disease; Limited disease; Refractory disease; Sensitive disease; Small cell lung cancer; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031932660     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-1-11     Document Type: Review

References (9)

1. Feld R, Ginsberg RJ, Payne DG et al. Lung. In: Abeloff MD, Armitage JO, Lichter AS et al., eds. Clinical Oncology. New York: Churchill Livingstone, Inc., 1995:1118-1141.
2. Takimoto CH, Arbuck SG. Camptothecins. In: Chabner BA, Long DL, eds. Cancer Chemotherapy and Biotherapy, Second Edition. Philadelphia: Lippincott-Raven, 1996:463-484.
3. O'Reilly S, Rowinsky EK, Slichenmeyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-3073.
4. Schiller JH, Kim K, Hutson P et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14:2345-2352.
5. Jett JR, Day R, Levitt M et al. Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 1997;18:13a.
6. Perez-Soler R, Glisson BS, Fossella FV et al. Treatment of patients with small cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-2790.
7. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan: a new active drug in the second-line treatment of small cell lung cancer. A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
8. Eckardt J, Gralia R, Palmer MC et al. Topotecan as second-line therapy in patients with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996;7(suppl 5):107a.
9. Schiller J, von Pawel J, Clarke P et al. Preliminary results of a randomized comparative phase III trial of topotecan versus CAV as second-line therapy of small cell lung cancer. Lung Cancer 1997;18:13a.